Exhibitor Stand List

Stand No. Company name


2 OPKO Biologics

OPKO Biologics (formerly: Prolor Biotech), a subsidiary of OPKO Health Inc., is a clinical stage company developing next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs, utilizing CTP and reversible PEGylation technologies. The CTP technology involves fusing one or more copies of a naturally occurring glycosylated peptide by rDNA technology to the protein chain ends. When attached to a therapeutic protein, CTP significantly extends its longevity in the body.

OPKO Biologics’ second technology is reversible PEGylation, a synthetic chemistry-based platform for enhancing the half-life of therapeutic peptides and small molecules. Using a hydrolysable linker bypasses the disadvantages of using a standard PEGylated molecule, i.e. the potential for steric hindrance that limits its function, and the limited ability to cross cellular membranes or the blood-brain barrier.

Using those two technologies, OPKO Biologics presents three bio-better long-acting products:

  • MOD-4023: CTP-modified human growth hormone (hGH). OPKO initiated a pivotal Phase 3 study in growth hormone-deficient (GHD) adults and is currently conducting an advanced Phase 2 study in a GHD pediatric population. The company completed a Phase 2 study in GHD adults, demonstrating that a single weekly injection of MOD-4023 could potentially substitute seven consecutive daily injections of regular hGH, and showing an excellent safety profile.
  • MOD-5014CTP-modified long-acting coagulation factor VIIa, potentiality supporting every-other-day prophylactic treatment or twice a week regimen in hemophilia patients. MOD-5014 is in an advanced pre-clinical development stage, targeted for Phase 2a by Q4 2015.
  • MOD-6031: long-acting reversibly PEGylated oxyntomodulin (OXM) for the treatment of type 2 diabetes and obesity. MOD-6031 injected once weekly for five weeks in obese and diabetic mice resulted in marked weight loss and glucose control, as compared to twice-daily injections of the native OXM peptide at the same dose. MOD-6031 is in advanced pre-clinical development, targeted for Phase 1 by Q1 2016.


3 ENSAT-CANCER Consortium

4 AdrenalNET (BijnierNET).

2015 was the first year BijnierNET (=AdrenalNET) has been in operation. BijnierNET is a cooperation of all parties concerned.
Nurses, doctors, patients, specialist and academic hospitals. We had to spend a great deal of our time designing, no blueprints were available.
Horizontaal integration (and no separated actions in vertical silos anymore) was new to the Dutch.

A small executive team was appointed to cope with the frequent contacts and all the new issues that required attention. In 2016 we will see further ambitious growth towards better care and quality of life for people with an adrenal gland disorder.

In this context, BijnierNET does focus on three healthcare spearheads:
1. Improving the quality of specialist-led chronic care
2. Improving diagnosis
3. Improving care in emergency situations.

Various activities in these key areas have already been started and will continue during 2016 and on into 2017. We do our utmost to create more international cooperation in improving of care for the adrenal patients.


6 Immunodiagnostic Systems PLC

Immunodiagnostic Systems PLC (IDS) is a leading in-vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. Our immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields.

As a leading diagnostics company, we aim to serve the needs of clinical laboratories worldwide by developing and supplying innovative solutions. Our high quality products improve laboratory efficiency and provide fast and accurate solutions to support diagnosis and therapy monitoring.

Our instrument platform, the IDS-iSYS Multi-Discipline Automated System, improves laboratory efficiency for our customers through its automated technology. The IDS-iSYS Multi-Discipline Automated System was launched in 2009 and continues to be manufactured in-house. We are dedicated to enhancing our customer’s experience by improving our technology through internal development programmes.

Our immunoassay portfolio is available as a combination of tests available for use on our fully-automated
IDS-iSYS Multi-Discipline Automated System, or as stand-alone manual test kits. This complete offering meets the needs of both clinical and research laboratories of all types and sizes with their diagnostic testing requirements.

Our IDS heritage within certain endocrinology fields, including Vitamin D testing, offers a solid platform to develop a market-leading endocrinology menu:

  •  Bone metabolism
  • Calcium metabolism
  • CKD-MBD (chronic kidney disease & mineral bone disorders)
  • Fertility
  • Growth disorders
  • Hypertension

To find out more about our immunoassay portfolio, please come and visit us on stand 6 or go to www.idsplc.com


8 Shire


Shire enables people with life altering-conditions to lead better lives.

We focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine. For more information please visit www.shire.com

9 HRA Pharma  


HRA Pharma is a leading pharmaceutical company with a unique leadership position within niche areas in women’s health and endocrinology/rare diseases. The company is committed to understand evolving health needs, bringing adequate health solutions and developing actions for equal access to its products amongst patients and physicians throughout the globe.

In the field of endocrinology/rare diseases our ambition is to make meaningful health solutions broadly accessible to rare disease patients. Currently, HRA Pharma has three treatment options in its portfolio that address Cushing’s Syndrome (CS) and Adrenal Cortical Carcinoma (ACC).

•Metopirone®/Metopiron®/Cormeto®/Metycor™ (metyrapone, 250 mg, soft capsule), a drug indicated, in 17 European countries, in the management of patients with endogenous Cushing's syndrome and, as a diagnostic test for ACTH insufficiency and as a diagnostic test in the differential diagnosis of ACTH-dependent Cushing's syndrome.

•Ketoconazole HRA™ (ketoconazole, 200 mg, tablet), newly registered as an orphan drug, specifically indicated for the treatment of endogenous Cushing’s  Syndrome in adults and adolescents above the age of 12 years.

•Lysodren® (mitotane, 500 mg, tablet), an orphan drug for the symptomatic treatment of advanced Adrenal Cortical Carcinoma (the effect of Lysodren® on non functional ACC is not established); and  its Lysosafe® Service, a free-of-charge mitotane plasma level monitoring service which helps physicians optimise efficacy and safety of Lysodren® treatment.

For more information, visit our corporate website www.hra-pharma.com

For any medical requests, please contact us at medinfo-od@hrapharma.com

10 Lilly    

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s
first commercial insulin. Today we are building upon this heritage by working to meet
the diverse needs of people with diabetes and those who care for them. Through research
and collaboration, a broad and growing product portfolio and a continued determination
to provide real solutions—from medicines to support programs and more—we strive to
make life better for all those affected by diabetes around the world.

For more information, visit www.lillydiabetes.com.




14 Strongbridge BioPharma  


Strongbridge Biopharma is a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases.

Strongbridge is currently developing three drug candidates for treatment of rare endocrine disorders; one for endogenous Cushing’s syndrome and two for acromegaly.

COR-003 (levoketoconazole), an investigational cortisol synthesis inhibitor, is our lead drug candidate, being studied as a treatment for endogenous Cushing’s syndrome. It has received orphan designation in the US and EU. SONICS, a phase 3 global clinical trial evaluating COR-003 is underway.

COR-004 and COR-005 are Phase 2 product candidates being investigated as treatments for acromegaly. COR-004 is an antisense oligonucleotide. COR-005 is a somatostatin analogue that has demonstrated differential inhibition of growth hormone and insulin, and has received orphan designation in the US and EU.

The safety and efficacy of COR-003, COR-004, and COR-005 have not been established.

Strongbridge is centered on Rare Focus, Rare Commitment, and Rare Passion. We are focused on bridging treatment gaps in rare diseases and are committed to achieving results for patients. Above all, we are passionate in our pursuit of new treatments that can make a positive difference in the lives of patients with rare diseases.

15 The Endocrine Society

16 NanoEnTek                                                        

NanoEnTek is a manufacturer of IVD instruments and disposables and is fast growing as a Global Top Digital POCT Creator. FREND system(Quantitative Fluorescent immunoassay Analyzer): Fastest(results in 5 minutes), Accurate(CE, FDA 510K cleared), Easy-to Use(3 steps). Please visit : www.nanoentek.com


17 Taylor & Francis              


Find the right journal for your research with Taylor & Francis Taylor & Francis publish more than 250 peer-reviewed journals spanning the complete spectrum of medicine – from bench to bedside and beyond. If you are looking to submit research, then we have a publication to match.

Explore our titles in Endocrinology. Visit www.tandfonline.com for more information about our titles, or drop by the Taylor & Francis stand at any time during the Congress.


18 Ipsen                                                               

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors.

Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US).

In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide.

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

19 Karger Publishers                                                       


Karger Publishers is a leading international publisher of medical and scientific journals and books. Currently, production comprises close to 100 scientific journals and about 50 book titles per year, both research and clinical, the majority of which are in English. Karger publications are indexed in all important bibliographical services, such as PubMed. Connecting people who want to share their knowledge with those who want to learn, the publisher's main concern is to provide high-quality content.

Publications in endocrinology include the book series 'Endocrine Development' (Series Editor: P.E. Mullis), 'Frontiers of Hormone Research' (Series Editor: E. Ghigo) and 'Frontiers in Diabetes' (Series Editors: M. Porta, F.M. Matschinsky). Visit our booth and browse our wide selection of books in adult and pediatric endocrinology. New publications include 'Neuroendocrine Tumors: A Multidisciplinary Approach', 'Imaging in Endocrine Disorders', 'Cortisol Excess and Insufficiency' and 'Novelties in Diabetes'.

Journals of particular interest to participants are the 'European Thyroid Journal' (Editor-in-Chief: W.M. Wiersinga), 'Hormone Research in Paediatrics' (Editor-in-Chief: S. Cianfarani), 'Neuroendocrinology' (Editor-in-Chief: R.P. Millar) and 'Obesity Facts' (Editor-in-Chief: H. Hauner) – free sample copies are available.

Publications are accessible online at www.karger.com/endocrinology with free abstracts, full-text search of articles and many other services.

20 Wisepress                                                       

Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.

21 Novo Nordisk    


Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries.

For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube


23 ECE 2017 Lisbon


The Portuguese Society of Endocrinology will be hosting the2017 European Congress of Endocrinology in Lisbon. We welcome all ECe2016 attendees to our booth to discover a little more about Lisbon, Portugal and the Portuguese Society of Endocrinology.

24 Phoenix Europe GmbH    


Phoenix Pharmaceuticals specialises in peptide assays for obesity, cardiovascular, diabetes and endocrine related hormones. Other products include endocrinology related peptides and antibodies. Our newer products are non-radioactive, highly sensitive fluorescent and chemiluminescent EIA assays as well as Magnetic Bead RIA assays which require as little as 5µl of sample. Irisin and Betatrophin related products are available now. Phoenix also offers the service of hormone level determination; where the tedious extraction and assay procedures are performed for you. Our long term experience in custom peptide synthesis and custom peptide labeling is appreciated by our customers as well. With over 40 obesity related peptides in publications today, Phoenix Pharmaceuticals is always the leader in obesity related peptide discoveries.


25 Pfizer                                                                               


At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com. Visit us: Booth #25


 26 Novartis Pharmaceuticals                              


Novartis Oncology is a global leader in improving outcomes for people living with cancer. We seek to transform cancer care through distinctive scientific and clinical strategies focused on developing targeted, immuno-oncology and combination therapies to create more effective options for patients. The company offers a wide range of innovative therapies and our oncology pipeline is one of the strongest and most productive in the industry. Our unique global capabilities support the strategy with research and broad operational facilities worldwide.

The robust R&D program has enabled Novartis Oncology to offer a wide range of mature and innovative patented products to help physicians meet patient needs, including Afinitor® (everolimus), Arzerra® (ofatumumab), Desferal® (deferoxamine), Exjade® (deferasirox), Farydak® (panobinostat), Femara® (letrozole), Glivec® (imatinib mesylate), Jakavi® (ruxolitinib), Mekinist™ (trametinib dimethyl sulfoxide), Odomzo® (sonidegib), Revolade® (eltrombopag olamine), Sandostatin® LAR® (octreotide), Signifor® (pasireotide), Tafinlar® (dabrafenib mesylate), Tasigna® (nilotinib), Tyverb® (lapatinib ditosylate), Votrient® (pazopanib hydrochloride), Zometa® (zoledronic acid) and Zykadia™(ceritinib). Novartis also has one of the broadest and most comprehensive oncology pipelines in the industry with more than 20 compounds in various stages of clinical trials.

We share a common goal with the global oncology community – to improve and extend the lives of patients. Through open partnerships with the community we gain and build knowledge, driving clinical development based on scientific and patient insights. Partnering with healthcare professionals enables us to conduct high-quality clinical trials with competitive timelines and aids in the discovery of new uses of our medicines. Engagement with advocacy groups helps us better understand patient needs and barriers to treatment success. Collaboration with health authorities helps us to speed delivery of new treatments for patients. More information can be found at: www.novartisoncology.com.


28 ESE

The European Society continues to grow with over 3000 members and is pleased to be celebrating its 10th Birthday this year during the Congress.  ESE is currently undergoing a strategic review to ensure that it has a clear direction and vision for the future, and would like to welcome you to come and have your say and talk to us on the stand. There will also be the opportunity to complete a short survey.

Ordinary membership is open to those with an interest in the field of endocrinology and hormonal systems.  In particular, the Society welcomes early-career endocrinologists, endocrine nurses and scientists.

Printed copies of the four official journals of the Society will be on display at our stand: European Journal of Endocrinology, Journal of Endocrinology, Journal of Molecular Endocrinology and Endocrine-Related Cancer.

In addition to this, information on Endocrine Connections, an interdisciplinary Open Access journal will be available.  Endocrine Connections is jointly-owned by the European Society of Endocrinology and the Society for Endocrinology: working together to further research, education and clinical practice in endocrinology.

ESE members receive free online access to all the journals as part of their membership.  Other membership benefits include:

  • Reduced rate print subscription to the European Journal of Endocrinology, Journal of Endocrinology, Journal of Molecular Endocrinology and Endocrine-Related Cancer
  • Reduced rate registration to the European Congress of Endocrinology and any other ESE events
  • Access to ESE Prizes, Grants and Awards
  • Access to a Members’ only section with access to a web-based directory of member endocrinologists
  • Tri-annual newsletter and regular email alerts advising of news and grants
  • Grants forum
  • Voting rights and attendance at general meetings 

Visit our stand to find out more information about ESE and our exciting activities or visit us online at www.ese-hormones.org

29 Patient Support Groups; including:

German Centre for Diabetes Research (DZD)         


The German Center for Diabetes Research (DZD) is a national association that brings together experts
in the field of diabetes research and combines basic research, translational research, epidemiology and
clinical applications. The aim is to develop novel strategies for personalized prevention and treatment of
diabetes. Members are Helmholtz Zentrum München – German Research Center for Environmental Health, the German Diabetes Center in Düsseldorf, the German Institute of Human Nutrition in Potsdam-Rehbrücke, the Paul Langerhans Institute Dresden of the Helmholtz Zentrum München at the University Medical Center Carl Gustav Carus of the TU Dresden and the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the Eberhard-Karls-University of Tuebingen together with associated partners at the Universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich.

More information: www.dzd-ev.de/en.


30   Thermo Fisher Scientific    




B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, investigates, develops and manufactures novel diagnostic testing procedures to improve early diagnosis and treatment of life threatening diseases. With high-quality immunodiagnostic tests for prenatal screening, cardiovascular, pulmonary, and cancer disorders as well as particularly for sepsis, the company contributes to the creation of a healthier future – to the greatest advantage for medical professionals and patients.

B·R·A·H·M·S GmbH is leading in specific market places and therapeutic areas. The aim of its basic research is to identify new biomarkers, with support by international co-operations and reputable research institution.

31 Endobridge                                                                 

On behalf of the Endocrine Society, European Society of Endocrinology and the Society of Endocrinology and Metabolism of Turkey, we are delighted to invite you to attend the fourth EndoBridge® meeting that will take place in Antalya, Turkey, October 20-23, 2016.

EndoBridge 2016 will provide a comprehensive update of recent advances in the full spectrum of endocrinology including diabetes and lipid disorders. The program involves state-of-the-art lectures delivered by world-renowned faculty as well as interactive case discussion sessions. 

The official language of the meeting is English and simultaneous translation in Russian, Arabic and Turkish will be provided. 

We expect EndoBridge 2016 to bring together leading experts of endocrinology and a diverse and active international scientific community of clinicians and fellows to present and discuss clinical endocrinology topics.

Antalya, the heart of the Turkish Riviera, is an exceptional venue blending history and culture with a majestic coastline of shiny beaches.

Please visit the EndoBridge® Booth to learn more about this event.